A Randomized, Double-Blind, Placebo Controlled Study Of The Efficacy, Safety, And Tolerability Of Serlopitant For The Treatment Of Pruritus In Adults And Adolescents With A History Of Atopic Dermatitis
Latest Information Update: 20 May 2021
At a glance
- Drugs Serlopitant (Primary)
- Indications Pruritus
- Focus Therapeutic Use
- Acronyms ATOMIK
- Sponsors VYNE Therapeutics
- 08 Apr 2018 Primary endpoint has not been met. (Itch Intensity - Numeric Rating Scale) According to the Menlo Therapeutics Media Release
- 08 Apr 2018 Results published in the Menlo Therapeutics Media Release
- 28 Mar 2018 According to the Menlo Therapeutics media release, treatment and follow-up period for all patients has been completed and results from this study are expected in April of 2018.